ClinicalTrials.gg
RecruitingNCT05928702Updated Jul 3, 2023

Temperature-elevating Armbaths for Arterial Hypertension

An interventional study of temperature-elevating armbath in Arterial Hypertension, sponsored by Kliniken Essen-Mitte. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Kliniken Essen-Mitte · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 282 studies in Hypertension with a site in Germany — 29 open to participants now, 46 under way, 11 of them phase 3. Hypertension · Germany.

Planned enrollment
211th of 250
50 · median 200
Started
2023
with 7 others
No phase
67 of 282
15 open now
Primary completion
2023-12
later than 3 of 45 live
Registered
250th of 282
by date

Among the 282 studies in Hypertension with a site in Germany, this one is the 211th largest by planned enrollment of the 250 interventional ones that give a count, is one of 8 that started in 2023, is one of 67 with no phase, reaches primary completion later than 3 of the 45 other live ones, and was the 250th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

29 of the 282 studies in Hypertension with a site in Germany are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 282 studies in Hypertension with a site in Germany, or all of them as a file.
02

Study summary

The goal of this randomized controlled trial is to learn about the effect of a hydrotherapeutic approach - a temperature-elevating armbath - in people with arterial hypertention. The main question[s] it aims to answer are:

  • Can this kind of hydrotherapy lower the blood pressure and therefore be an additional approach to medical treatment in arterial hypertension?
  • Besides blood pressure regulation, does this intervention affect sleep quality when being performed at night time or does it affect overall quality of life?

Participants will be advised to perform a temperature-elevating armbath once a day for 30 minutes on at least 5 days per week over 8 weeks.

The comparison group will continue treatment as usual, like continue their medication. 24h blood pressure measurements will be performed at the beginning, after 8 weeks and after 6 months in both groups. The main goal is to evaluate whether the intervention group shows lower blood pressure levels after a certain time of treatment.

After 6 months (end of trial) the control group will be offered to learn the temperature elevating armbath as well.

Read the detailed description

Arterial hypertension remains one of the most important risk factors in developing a cardiovascular disease. While medical treatment is usually necessary, lifestyle modifications should always be included. Besides physical activity and a balanced diet, there are also therapeutic approaches from the so called classical complementary medicine. One very important part in Europe is hydrotherapy, based on ideas of Sebastian Kneipp and his contemporaries. In hydrotherapy there are various therapeutic approaches that can be used additionally to conventional therapy. Because conventional medical therapy is often associated with unwanted side effects, these additional approaches experience increasing popularity. In arterial hypertension, temperature-elevating armbaths, developed by Kneipps contemporaries Hauffe and Schwenninger, are a hydrotherapeutic approach that is highly recommended. Even though hydrotherapy has been a part of complementary medicine for more than a century now some therapeutic approaches lack of scientific evidence - especially when it comes to their effect on arterial hypertension.

This randomized-controlled trial aims to evaluate the effect of a temperature-elevating armbath among participants with arterial hypertension. 50 participants will be randomized to either an intervention group or waitlist (treatment as usual). All 50 participants will be monitored with three 24-hours ambulatory blood pressure measurements (24h ABPM) at the beginning of the trial after randomization, at 8 weeks and at 6 months.

The intervention group will be advised to perform the armbaths on 5 of 7 days per week for 8 weeks total. Each participant will get a detailed instruction how to perform the armbath and will be handed a diary to document their performance.

After 6 months, each participant of the control group will be offered to be instructed on performing the armbaths as well.

Within the active period of 8 weeks, participants of both groups will be called regularly to ask about their health and whether they have questions regarding the trial.

03

Conditions studied

  • Arterial Hypertension

Browse trials for

Keywords

  • Complementary Medicine
  • Hydrotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult participants (≥18 years)
  • diagnosed arterial hypertension, at least stage I, based on the Guidelines of the European Society of Hypertension 2018 (systolic >140 mmHg, diastolic >90 mmHg)
  • last change in medication at least 2 months ago
  • no planned changes in blood pressure medication within intervention time; changes due to medical reasons (e.g., hypotension, hypertensive emergency) are allowed.
  • willingness to perform an armbath on a regular schedule (min. 5x/weeks)

Exclusion criteria

Exclusion Criteria:

  • acute psychiatric disease ( e.g., addiction, major depression)
  • acute or major physical disease (e.g., cancer diagnosis within the last 5 years, major known cardiovascular diseases, renal or liver dysfunction), acute infection, major neurological diseases (e.g., Parkinsons´ disease, uncontrolled epilepsy)
  • secondary hypertension
  • pregnancy or lactation period
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Armbath

    The armbath group will perform a temperature-elevating armbath developed by Hauffe and Schwenninger. A large bowl and a thermometer will be given to each participant. Participant start with bathing their forearms up to about one third of the upper arm in a large bowl with water at approximately 37°C. Within 30min, they are advised to add hot water to the bowl for multiple times until a temperature of 42°C. After 30min, the arms can be taken out of the water, dried, and participants are recommended to rest for additional 30 min afterwards. Prior medication should be continued throughout the whole trial.

    Procedure: temperature-elevating armbath

  • No intervention
    Waitlist

    Participants will continue their treatment as usual (e.g. medication). After the end of the trial (6 months) they will be offered to get instructed on performing temperature-elevating armbaths.

Interventions

  • Proceduretemperature-elevating armbath

    Hydrotherapeutic Approach

06

What researchers measure

Primary outcomes

  1. Blood pressure

    Time frame: to 8 weeks

Secondary outcomes

  1. Blood pressure

    Time frame: to 6 months

  2. SF-12

    Health-related quality of life

    Time frame: to 8 weeks and 6 months

  3. PSQI

    Sleep quality

    Time frame: to 8 weeks and 6 months

  4. heartrate

    Time frame: to 8 weeks and 6 months

  5. Adverse events

    Time frame: to 8 weeks and 6 months

  6. Medication

    Monitoring of changes in medication

    Time frame: to 8 weeks and 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Blood pressure measurements, Comorbidities, medication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2023, 6 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 6 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2023
First posted
Jul 3, 2023
StartActual
Jun 23, 2023
Primary completionEst.
Dec 23, 2023
CompletionEst.
Jun 24, 2024
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05928702
Lead sponsor
Kliniken Essen-Mitte
Collaborators
Karl and Veronica Carstens Foundation
Responsible party
Kohl, Wiebke (MD, Kliniken Essen-Mitte) — Principal investigator
First posted
Jul 3, 2023
Start date
Jun 23, 2023
Primary completion
Dec 23, 2023 (estimated)
Completion
Jun 24, 2024 (estimated)
Last update
Jul 3, 2023

Study contacts

Wiebke Kohl-Heckl, MD
Contact
w.kohl@kem-med.com
004920117425058

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion